苏沃雷生的药理学与临床评价

发布时间：2018-06-23 18:59

本文选题：苏沃雷生 + 催眠药　；参考：《中国临床药理学杂志》2015年18期

【摘要】：苏沃雷生为一新型催眠药,是第一个批准治疗失眠的食欲素受体拮抗剂,其药理作用机制为双重食欲素OX1R和OX2R受体抑制剂,用于入睡或睡眠维持困难的治疗。苏沃雷生每晚入睡前30 min服用10 mg,每次最大剂量为20mg,对失眠症的治疗有效且耐受性较好。常见的不良反应是嗜睡、头痛和口干。本文对苏沃雷生的药理学、药代动力学、临床评价和安全性等进行介绍。
[Abstract]:Suvoresen, a new hypnotic, is the first orexin receptor antagonist to approve the treatment of insomnia. Its pharmacological mechanism is dual orexin OX1R and OX2R receptor inhibitors, which are used in the treatment of sleep or sleep maintenance difficulties. Suvorelson took 10 mg every night 30 min before falling asleep, with a maximum dose of 20 mg each time, which was effective and tolerated in the treatment of insomnia. Common adverse effects are drowsiness, headache and dry mouth. The pharmacology, pharmacokinetics, clinical evaluation and safety of suvorexen were reviewed.
【作者单位】：新乡医学院第二附属医院药学部;新乡医学院第二附属医院河南省生物精神病学重点实验室;
【基金】：河南省卫生科技创新型人才工程基金资助项目(3052)
【分类号】：R96

【相似文献】